Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
Cross-talk between epidermal growth factors and the ER occurs at multiple levels and seems to
play a crucial role in breast cancer progression and endocrine resistance.Combined
HER1/HER2-targeted therapy with aromatase inhibitors for ER-positive and HER-2 positive
postmenopausal breast cancer might enhance response and block emergence of endocrine
resistant tumor.